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of similar structural and pharmacologic characteristics, such as fen-
fluramine and dexfenfluramine (brand names Ponderal®, Isomeride®; 
Servier, Redux®; Wyeth) have been withdrawn from the world 
market since 1997. Indeed, these compounds, derived from the 
amphetamines, are known to be responsible for pulmonary arterial 
hypertension (PAH) and valvular heart disease (VHD). Subsequent 
studies published in 2000 have shown the determinant role of their 
common active metabolite, norfenfluramine, which is present at 
equal plasma concentrations after fenfluramine, dexfenfluramine, 
or benfluorex intake at recommended dosages. Norfenfluramine 
induces VHD and PAH by stimulation of a serotonin receptor sub-
type, expressed on both aortic and mitral valve leaflets as well as in 
pulmonary arteries.
Despite several case reports stressing the association of PAH 
and/or VHD with benfluorex exposure, benfluorex remained avail-
able in France until November 2009. Our initial case-control study 
published in 2010 put forward the toxicity and the VHD risk of 
benfluorex, thus leading to the withdrawal of benfluorex from the 
European and world market, respectively. This pilot study opened 
the avenue to further pharmacoepidemiologic studies validating 
our results and giving detailed data on the benfluorex risks in larger 
populations.
Actual human consequences of longer than 33 years of marketing 
authorization of benfluorex on patients only in France are estimated 
at ~1300 to 1800 deaths and 3100 to 4200 VHD-related hospitali-
zations. To date, there is no estimation of worldwide mortality due 
to benfluorex use.
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Summary: Recent public discussion on new treatment options in 
orphan diseases has focused on the great promise they hold, as well 
as the high cost they generate for our health systems. Instead, this 
presentation will consider new facts and difficulties arising from these 
treatments from a purely medical standpoint and discuss some of 
them using examples from our daily practice.
Enzyme-replacement therapy (ERT) for certain lysosomal stor-
age disorders (LSD) does not cross the blood-brain barrier (BBB) 
and does not, therefore, influence disease progression in the brain. 
How should we take into account the extent and speed of progress 
of lysosomal brain disease? Even at the peripheral level, definition 
of satisfactory treatment, efficacy is not straightforward. Miglustat, 
an example for substrate reduction therapy, has the advantage to 
cross the BBB. Recently, it has been used in several neuronopathic 
LSD, including early-manifesting Gaucher type III disease. What is 
the impact of inhibiting the synthesis of complex molecules in a brain 
that is still under construction? What benefice can be expected and 
at what age?
Sapropterin (Kuvan®) is a pharmacologic chaperone that has 
recently been introduced for the treatment of phenylketonuria. There 
is, however, a wide interindividual variation of response to this drug; 
it can in only rare instances completely replace the equally or more 
effective dietary treatment. Treatment policies vary among countries 
and even within countries.
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Summary: At least 6 members of the family of the transient receptor 
potential (TRP) channels are expressed in defined subpopulations of 
primary sensory neurons (nociceptors), where they mediate acute 
nociceptive responses and contribute to allodynic and hyperalgesic 
conditions. Most prominent channels are the vanilloid 1 (TRPV1), 
which is activated by capsaicin, protons, and certain eicosanoids, 
and the ankyrin 1 (TRPA1). TRPA1 is uniquely gated by an unprece-
dented series of reactive exogenous (mustard oil, cinnamaldehyde and 
others) and endogenous molecules. These latter molecules include 
byproducts of oxidative stress, as hydrogen peroxide, 4-hydroxynon-
enal, oxononenal, and many others electrophilic agonists, which, 
by binding to key cysteine residues, cause channel activation and 
nociceptor stimulation. All TRPA1-expressing neurons and the 
majority of TRPV1-expressing neurons express and release sensory 
neuropeptides, which mediate neurogenic inflammatory responses. 
Calcitonin gene–related peptide (CGRP) released from perivascu-
lar trigeminal nerve endings upon TRPV1 or TRPA1 stimulation 
has been now recognized as a major contributing factor of migraine 
headaches. A series of agents, known to trigger migraine attacks, 
have been identified as selective stimulants of TRPV1 or TRPA1, 
thereby producing CGRP-dependent meningeal vasodilatation. There 
is growing evidence that TRPV1 and, even at a larger extent, TRPA1 
contribute to thermal and mechanical hypersensitivity in models of 
inflammatory and neuropathic pain. In particular, recent findings 
underscore the critical role of TRPA1 in models of chemotherapeutic-
induced peripheral neuropathy. The desensitizing action on noci-
ceptor function of topical and repeated application of the TRPV1 
agonist, capsaicin, has been used for a long time for the treatment of 
pain in postherpetic neuralgia and in diabetic neuropathy. In contrast, 
clinical development of TRPV1 antagonists has been hampered by 
unexpected evidence obtained in Phase I studies of their ability to 
increase body temperature and heat pain threshold. The underlying 
hypothesis that TRPA1 plays a major role in pain associated with 
increases in oxidative stress is boosting major efforts in the discovery 
and development of TRPA1 antagonists.
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Summary: Knowledge of the driving molecular abnormalities 
that underlie the malignant phenotype has afforded opportunity 
to pharmacologically, and with surgical precision, target cancers. 
Historically, therapy for hematologic malignancies has been associ-
ated with toxicity to normal bone marrow and lymphoid progeni-
tors. This results in myelosuppression and immunosuppression. The 
discovery of the Philadelphia chromosome t (9:22) and subsequent 
clarification that t (9:22)(q34:q11) resulted in the expression of the 
chimeric growth–promoting protein BCR-ABL led to the development 
